Literature DB >> 19734356

VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B.

Mitsuho Onimaru1, Yoshikazu Yonemitsu, Takaaki Fujii, Mitsugu Tanii, Toshiaki Nakano, Kazunori Nakagawa, Ri-ichiro Kohno, Mamoru Hasegawa, Shin-ichi Nishikawa, Katsuo Sueishi.   

Abstract

Emerging evidence indicates that the tight communication between vascular endothelial cells and mural cells using platelet-derived growth factor (PDGF)-BB is essential for capillary stabilization during the angiogenic process. However, little is known about the related regulator that determines PDGF-BB expression. Using murine models of therapeutic neovascularization, we here show that a typical lymphangiogenic factor, vascular endothelial growth factor (VEGF)-C, is an essential regulator determining PDGF-BB expression for vascular stabilization via a paracrine mode of action. The blockade of VEGF type 3 receptor (VEGFR3) using neutralizing antibody AFL-4 abrogated FGF-2-mediated limb salvage and blood flow recovery in severely ischemic hindlimb. Interestingly, inhibition of VEGFR3 activity not only diminished lymphangiogenesis, but induced marked dilatation of capillary vessels, showing mural cell dissociation. In these mice, VEGF-C and PDGF-B were upregulated in the later phase after induced ischemia, on day 7, when exogenous FGF-2 expression had already declined, and blockade of VEGFR3 or PDGF-BB activities diminished PDGF-B or VEGF-C expression, respectively. These results clearly indicate that VEGF-C is a critical mediator, not only for lymphangiogenesis, but also for capillary stabilization, the essential molecular mechanism of communication between endothelial cells and mural cells during neovascularization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19734356     DOI: 10.1152/ajpheart.00015.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  19 in total

1.  Vascular endothelial growth factor-C ameliorates renal interstitial fibrosis through lymphangiogenesis in mouse unilateral ureteral obstruction.

Authors:  Shoko Hasegawa; Toshiaki Nakano; Kumiko Torisu; Akihiro Tsuchimoto; Masahiro Eriguchi; Naoki Haruyama; Kosuke Masutani; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  Lab Invest       Date:  2017-10-30       Impact factor: 5.662

2.  SDF-1α induces PDGF-B expression and the differentiation of bone marrow cells into pericytes.

Authors:  Randala Hamdan; Zhichao Zhou; Eugenie S Kleinerman
Journal:  Mol Cancer Res       Date:  2011-09-12       Impact factor: 5.852

3.  Intra-articular clearance of labeled dextrans from naive and arthritic rat knee joints.

Authors:  Timothy K Mwangi; Ian M Berke; Eduardo H Nieves; Richard D Bell; Samuel B Adams; Lori A Setton
Journal:  J Control Release       Date:  2018-05-26       Impact factor: 9.776

4.  E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B.

Authors:  David Engelmann; Deborah Mayoli-Nüssle; Christian Mayrhofer; Katharina Fürst; Vijay Alla; Anja Stoll; Alf Spitschak; Kerstin Abshagen; Brigitte Vollmar; Sophia Ran; Brigitte M Pützer
Journal:  J Mol Cell Biol       Date:  2013-09-06       Impact factor: 6.216

5.  Dysmorphogenesis of lymph nodes in Foxc2 haploinsufficient mice.

Authors:  Hiroshi Shimoda; Michael J Bernas; Marlys H Witte
Journal:  Histochem Cell Biol       Date:  2011-05-26       Impact factor: 4.304

6.  Cooperative Effects of Vascular Angiogenesis and Lymphangiogenesis.

Authors:  Tatsuya Osaki; Jean C Serrano; Roger D Kamm
Journal:  Regen Eng Transl Med       Date:  2018-04-23

7.  Vascular endothelial growth factor C attenuates joint damage in chronic inflammatory arthritis by accelerating local lymphatic drainage in mice.

Authors:  Quan Zhou; Ruolin Guo; Ronald Wood; Brendan F Boyce; Qianqian Liang; Yong-Jun Wang; Edward M Schwarz; Lianping Xing
Journal:  Arthritis Rheum       Date:  2011-08

8.  Vascular endothelial growth factor c/vascular endothelial growth factor receptor 3 signaling regulates chemokine gradients and lymphocyte migration from tissues to lymphatics.

Authors:  Daiki Iwami; C Colin Brinkman; Jonathan S Bromberg
Journal:  Transplantation       Date:  2015-04       Impact factor: 4.939

9.  DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial.

Authors:  Yoshikazu Yonemitsu; Takuya Matsumoto; Hiroyuki Itoh; Jin Okazaki; Makiko Uchiyama; Kumi Yoshida; Mitsuho Onimaru; Toshihiro Onohara; Hiroyuki Inoguchi; Ryoichi Kyuragi; Mototsugu Shimokawa; Hiroshi Ban; Michiko Tanaka; Makoto Inoue; Tsugumine Shu; Mamoru Hasegawa; Yoichi Nakanishi; Yoshihiko Maehara
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

Review 10.  Tissue engineering and regeneration of lymphatic structures.

Authors:  Evan Weitman; Daniel Cuzzone; Babak J Mehrara
Journal:  Future Oncol       Date:  2013-09       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.